Similar articles for PMID: 24859998

Year	Number of Results
2005	1
2006	1
2007	1
2009	1
2010	2
2011	3
2012	4
2013	6
2014	16
2015	19
2016	12
2017	15
2018	12
2019	18
2020	29
2021	35
2022	48
2023	20
2024	0

1

KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study.

Negru S, Papadopoulou E, Apessos A, Stanculeanu DL, Ciuleanu E, Volovat C, Croitoru A, Kakolyris S, Aravantinos G, Ziras N, Athanasiadis E, Touroutoglou N, Pavlidis N, Kalofonos HP, Nasioulas G. Negru S, et al. BMJ Open. 2014 May 23;4(5):e004652. doi: 10.1136/bmjopen-2013-004652. BMJ Open. 2014. PMID: 24859998 Free PMC article.

2

RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer.

Ta TV, Nguyen QN, Chu HH, Truong VL, Vuong LD. Ta TV, et al. Pathol Res Pract. 2020 Apr;216(4):152898. doi: 10.1016/j.prp.2020.152898. Epub 2020 Feb 17. Pathol Res Pract. 2020. PMID: 32089414

3

Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?

Yang L, Dong D, Fang M, Zhu Y, Zang Y, Liu Z, Zhang H, Ying J, Zhao X, Tian J. Yang L, et al. Eur Radiol. 2018 May;28(5):2058-2067. doi: 10.1007/s00330-017-5146-8. Epub 2018 Jan 15. Eur Radiol. 2018. PMID: 29335867

4

Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR.

Nagakubo Y, Hirotsu Y, Amemiya K, Oyama T, Mochizuki H, Omata M. Nagakubo Y, et al. BMC Med Genomics. 2019 Nov 11;12(1):162. doi: 10.1186/s12920-019-0610-8. BMC Med Genomics. 2019. PMID: 31711486 Free PMC article.

5

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.

Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. Therkildsen C, et al. Acta Oncol. 2014 Jul;53(7):852-64. doi: 10.3109/0284186X.2014.895036. Epub 2014 Mar 25. Acta Oncol. 2014. PMID: 24666267 Review.

6

Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.

Peeters M, Kafatos G, Taylor A, Gastanaga VM, Oliner KS, Hechmati G, Terwey JH, van Krieken JH. Peeters M, et al. Eur J Cancer. 2015 Sep;51(13):1704-13. doi: 10.1016/j.ejca.2015.05.017. Epub 2015 Jun 3. Eur J Cancer. 2015. PMID: 26049686

7

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.

Hsu HC, Thiam TK, Lu YJ, Yeh CY, Tsai WS, You JF, Hung HY, Tsai CN, Hsu A, Chen HC, Chen SJ, Yang TS. Hsu HC, et al. Oncotarget. 2016 Apr 19;7(16):22257-70. doi: 10.18632/oncotarget.8076. Oncotarget. 2016. PMID: 26989027 Free PMC article.

8

Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases.

Zhang J, Zheng J, Yang Y, Lu J, Gao J, Lu T, Sun J, Jiang H, Zhu Y, Zheng Y, Liang Z, Liu T. Zhang J, et al. Sci Rep. 2015 Dec 22;5:18678. doi: 10.1038/srep18678. Sci Rep. 2015. PMID: 26691448 Free PMC article.

9

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.

Kawazoe A, Shitara K, Fukuoka S, Kuboki Y, Bando H, Okamoto W, Kojima T, Fuse N, Yamanaka T, Doi T, Ohtsu A, Yoshino T. Kawazoe A, et al. BMC Cancer. 2015 Apr 11;15:258. doi: 10.1186/s12885-015-1276-z. BMC Cancer. 2015. PMID: 25886136 Free PMC article.

10

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S. De Roock W, et al. Lancet Oncol. 2010 Aug;11(8):753-62. doi: 10.1016/S1470-2045(10)70130-3. Epub 2010 Jul 8. Lancet Oncol. 2010. PMID: 20619739

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

213 results

Results by year